Lineage Cell Therapeutics Virtual Event

June 10, 2021

Please join Lineage Cell Therapeutics for a webinar with therapeutic area experts to discuss the first reported findings of retinal tissue regeneration in patients with Dry AMD with Geographic Atrophy. Lineage recently reported that restoration of retinal tissue has been observed in three patients enrolled in the Company’s Phase 1/2a study of its lead product candidate, OpRegen, an allogeneic retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of AMD with geographic atrophy (GA), or dry (atrophic) AMD.

Therapeutic Area Experts

JordiMones_2015_IMIR1-300x450_pybue4.jpg

image_u77hm5.pngimage_fxubns.png

Jordi Monés, M.D., Ph.D., Director of the Institut de la Màcula and Director, Principal Investigator and one of the founder governors of the Barcelona Macula Foundation: Research for Vision.

Dr. Monés is an ophthalmologist, macula and vitreoretinal specialist, and macular and retinal degeneration researcher. Dr. Monés earned his medical degree at the University of Barcelona and subsequently specialized in ophthalmology at Barraquer Ophthalmology Centre. He earned his retinal specialist degree at the Massachusetts Eye and Ear Infirmary at Harvard University, and at Hospital San José, Monterrey Institute of Technology and Higher Education. He earned his PhD degree at the University of Barcelona. Dr Monés is dedicated to fighting blindness by supporting and conducting research in retinal disease. For the last 15 years he has been one of the foremost researchers involved in clinical trials for the treatment of age-related macular degeneration. He is currently conducting Phase I, II and III clinical trials. His work has been widely published in scientific journals and he has given more than 200 presentations at international congresses. He is a member of 12 scientific societies.

Banin_Eyal_Headshot_snippingt_z2dv9d.png

 

image_su9w74.png

Eyal Banin, M.D., Ph.D., Director, Center for Retinal and Macular Degenerations (CRMD), Department of Ophthalmology, Hadassah-Hebrew University Medical Center.

Dr. Banin is a graduate of the Hebrew University-Hadassah School of Medicine, holds a Ph.D. in Neurobiology from the Hebrew University, and completed his ophthalmology residency at Hadassah Medical Center. Following a post-doctoral and medical retina fellowship at the University of Pennsylvania’s Scheie Eye Institute in Philadelphia, he was appointed head of the Medical Retina Service and the CRMD at Hadassah. His main clinical and research focus is in the field of retinal and macular degenerations, including the development and application of novel cell- and gene-based therapies for these diseases. The recipient of many research grants from Israeli and foreign institutions, Dr. Banin has authored and published over 150 peer-reviewed articles in leading medical and scientific journals.

OHSU-Lujan_Brandon_Headshot_b36puz.jpg

 

image_2jvuud.png

Brandon Lujan, M.D., Associate Professor of Ophthalmology, School of Medicine, OHSU Casey Eye Institute.

Dr. Lujan is a medical retina specialist, scientist, and Director of the Casey Reading Center. Dr. Lujan’s area of expertise is Optical Coherence Tomography (OCT) retinal imaging, and he is the first-named inventor and co-developer of Directional OCT, a technique and device capable of creating optical contrast in photoreceptors. Dr. Lujan has published and spoken internationally on diagnosis and management of macular diseases and has brought that expertise to bear on clinical trials. He is the creator of OCTMD, an educational resource focused on the present and future of OCT. Dr. Lujan is a member of the Macula Society, Retina Society, the Association for Research and Vision in Ophthalmology, and the American Society of Retina Specialists.

Riemann-MD-_fcpqkr.jpeg

 

image_3emsn7.png

Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine.

In collaboration with the other Retinal Surgeons at CEI, Dr. Riemann is a principal investigator or co-investigator for many Phase two and Phase three FDA trials. He specializes in medical and surgical vitreoretinal diseases including diabetic retinopathy, macular degeneration, retinal detachment, retinopathy of prematurity, vascular diseases of the retina, uveitis, histoplasmosis, complications of anterior segment surgery, endoscopic posterior segment surgery, and ocular trauma. Dr. Riemann is a member of the American Society of Retina Specialists, American Academy of Ophthalmology, Ohio State Medical Association, Cincinnati Academy of Medicine, Cincinnati Ophthalmology Society, and the Association for Research in Vision and Ophthalmology. His original research in the fields of Ophthalmology, Cardiology, and Endocrinology has been published in international peer reviewed scientific journals and has been presented at national scientific meetings. He has several patents for innovative surgical technologies and enjoys sharing his passion for the blend of engineering and medicine.

Ip_Michael_MD_Headshot_fkmkge.png


image_wsnmpz.png

Michael S. Ip, M.D., Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.

Dr. Ip is a member of the Doheny Eye Institute and currently serves as the Medical Director of the Doheny Image Reading Center. His research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, AMD, and retinal venous occlusive disease and other retinal diseases. Dr. Ip has assisted with the collection, analysis, and dissemination of important primary and secondary outcomes in ophthalmic clinical trials. In 2003, Dr. Ip was selected to serve as the national protocol chair for the clinical trial conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema (protocol B). This was a landmark study and changed practice patterns in the field of ophthalmology. In 2003, his independent and investigator-initiated research group received a U-10 cooperative agreement award from the National Eye Institute, National Institutes of Health to conduct the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study. This was a multicenter, randomized, NIH-defined phase 3 trial which led to over 15 publications in the peer-reviewed literature and provided much needed Level 1 evidence to guide our management of retinal venous occlusive disease. In 2013, this group received funding from the NEI to conduct the SCORE2 Study. The SCORE2 Study is an NIH-defined phase 3 clinical trial designed to evaluate the comparative efficacy and safety of bevacizumab versus aflibercept for the treatment of macular edema secondary to central retinal vein occlusion. It has been designed to answer several questions of significant public health importance. Currently, this study group has extended the SCORE2 follow up phase to evaluate long-term safety and efficacy outcomes in central retinal vein occlusion.

 

A live webcast of the event will be available at the link below or on the Events and Presentations section of Lineage’s website or click below.

RSVP Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Lineage Cell Therapeutics Inc. [LCTX] $382 MM MCap
Cell ther­a­py com­pany with 3 clin­i­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]